Meanwhile, other groups have tried to improve DC efficacy with the use of local induction of FMS-related tyrosine kinase 3 (FLT3), whose signaling is key to the recruitment and expansion of DCs at the tumor site [131]. This evidence concerns the gene FLT3 and neoplasm.